Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
December 5, 2019
Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology
December 4, 2019
Revance Announces Pricing of Public Offering of Common Stock
December 3, 2019
Revance Announces Proposed Public Offering of Common Stock
December 2, 2019
Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics
November 25, 2019
Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines
November 12, 2019
Revance to Participate in the Stifel 2019 Healthcare Conference
November 6, 2019
Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference
November 4, 2019
Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update
November 4, 2019
Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia
November 4, 2019
Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery
Displaying 91 - 100 of 278